Sunday, December, 08, 2019 06:25:53

Growing prevalence of cardiovascular diseases across the globe have increased the risk of reperfusion injury in patients. While strong R&D activities from prominent players in the medical market are propelling the cardiovascular therapy market, various firms are also working towards the development of treatment options for reperfusion injuries.

Faraday Pharmaceuticals, a US-based biopharmaceutical company aimed at the development of novel treatments for ischemia-reperfusion injury, reportedly announced that it would be presenting clinical data of FDY-5301 from a Phase 2 trial at the 2019 AHA (American Heart Association) Scientific Sessions.

The 2019 American Heart Association Scientific Session would be conducted between 16 and 18 November in Philadelphia, Pennsylvania. The AHA event would highlight the forthcoming advancements in medicine and cardiovascular science.

Faraday is a company that is dedicated towards the creation of new elemental reducing agents that further enhance patient outcomes from critical-care diseases by lowering loss of skeletal as well as cardiac muscle function.

FDY-5301 is a novel patented, elemental reducing agent (ERA) which contains sodium iodide. The primary function of this agent is to destroy hydrogen peroxide that is a naturally generated in response to acute injury and is responsible for the loss of muscle as well as muscle function.

Preclinical assessments of FDY-5301 have showcased the potential of this agent to improve cardiac function, decrease infarct size, and enhance skeletal muscle function. Additionally, data from Phase 1 study has demonstrated no toxicity signs within healthy subjects.

Faraday, which is working to find an effective solution to prevent muscle loss following the treatment of a serious diseases, had initiated the Phase 1 trial of FDY-5301 in September 2016.  The trial had enrolled about 40 patients and was carried out in Australia.

Recently, the company raised $25 million from ARCH Venture Partner, and Polaris among other companies to strengthen its capabilities for innovation in muscle loss prevention research.

 

Source credit: http://faradaypharma.com/news/faraday-pharmaceuticals-announces-presentation-of-clinical-data-from-phase-2-trial-of-fdy-5301-at-the-american-heart-association-scientific-sessions-2019